Download PDF
Fortschr Neurol Psychiatr 2024; 92(07/08): 267-276
DOI: 10.1055/a-2331-0783
Übersichtsarbeit

CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)

CGRP: from neuropeptide to the therapeutic target (background and pathophysiology)
Katharina Kamm
1   Neurologische Klinik und Poliklinik, LMU Klinikum Campus Grosshadern, Ludwig-Maximilians-Universität München, München, Germany (Ringgold ID: RIN27192)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Calcitonin Gene-related Peptide (CGRP) spielt eine zentrale Rolle in der Pathophysiologie der Migräne. Die Bedeutung von CGRP für die Migräne ist aus zahlreichen klinischen Studien mit Nachweis von erhöhten CGRP-Spiegeln iktal und interiktal sowie der Wirksamkeit der CGRP-basierten Therapien bekannt. In der vorliegenden Arbeit werden diese Studien vorgestellt und so der Weg zur Entwicklung der CGRP-basierten Medikamente aufgezeigt. Abschließend werden aktuelle Studienergebnisse in Bezug auf die CGRP-Rezeptorantagonisten, die sogenannten Gepante, vorgestellt.

Abstract

Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine pathophysiology. The importance of CGRP in migraine became evident from numerous clinical studies investigating CGRP levels both interictally and ictally and reports on the efficacy of CGRP-based migraine therapies. In this paper, the above mentioned studies will be presented and the reader will be introduced to the development of CGRP-based medication. Finally, current study results on CGRP receptor antagonists, the so-called gepants, will be presented.

Schlüsselwörter

Migräne - Kopfschmerz - Calcitonin Gene-related Peptid - CGRP-Rezeptorantagonisten

Keywords

migraine - headache - CGRP receptor antagonists - Calcitonin gene-related peptide


Publication History

Received: 13 November 2023

Accepted after revision: 15 May 2024

Article published online:
18 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiological reviews 2023; 103: 1565-644.
    CrossrefPubMedSearch in Google Scholar
  • 2 Russell FA, King R, Smillie S-J, Kodji X, Brain S. Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews 2014; 94: 1099-1142
    CrossrefPubMedSearch in Google Scholar
  • 3 Meßlinger K. Bedeutung des „calcitonin gene-related peptide“ (CGRP) in der Pathophysiologie von Migräne und Clusterkopfschmerz. Der Schmerz 2020; 34: 181-187
    CrossrefPubMedSearch in Google Scholar
  • 4 Edvinsson L. CGRP and migraine: from bench to bedside. Revue neurologique 2021; 177: 785-790
    CrossrefPubMedSearch in Google Scholar
  • 5 Messlinger K. The big CGRP flood-sources, sinks and signalling sites in the trigeminovascular system. The Journal of Headache and Pain 2018; 19: 1-7
    CrossrefPubMedSearch in Google Scholar
  • 6 McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proceedings of the National Academy of Sciences 1986; 83: 5731-5735
    CrossrefPubMedSearch in Google Scholar
  • 7 Kamm K. CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?. Front Neurol.. 2022 Jul 27 13. 930383
    CrossrefPubMedSearch in Google Scholar
  • 8 Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nature Reviews Neurology 2018; 14: 338
    CrossrefPubMedSearch in Google Scholar
  • 9 Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1990; 28: 183-187
    CrossrefPubMedSearch in Google Scholar
  • 10 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1993; 33: 48-56
    CrossrefPubMedSearch in Google Scholar
  • 11 Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G. et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-390
    CrossrefPubMedSearch in Google Scholar
  • 12 Ashina M, Hansen JM, Á Dunga BO, Olesen J Human models of migraine – short-term pain for long-term gain. Nature reviews Neurology. 2017 13. 713
    PubMedSearch in Google Scholar
  • 13 Juhász G, Zsombok T, Jakab B, Nemeth J, Szolcsányi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005; 25: 179-183
    CrossrefPubMedSearch in Google Scholar
  • 14 Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J. et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461-70.
    CrossrefPubMedSearch in Google Scholar
  • 15 Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C. et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 2006; 26: 257-265
    CrossrefPubMedSearch in Google Scholar
  • 16 Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J. et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023 94. 285-294 Epub 2023 Apr 21
    CrossrefPubMedSearch in Google Scholar
  • 17 Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000; 86: 133-138
    CrossrefPubMedSearch in Google Scholar
  • 18 Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81: 1191-1196
    CrossrefPubMedSearch in Google Scholar
  • 19 Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A. et al. CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine: an observational study. Headache: The Journal of Head and Face Pain 2018; 58: 78-87
    CrossrefPubMedSearch in Google Scholar
  • 20 Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007; 128: 209-214
    CrossrefPubMedSearch in Google Scholar
  • 21 Lee MJ, Lee S-Y, Cho S, Kang E-S, Chung C-S. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. The journal of headache and pain 2018; 19: 53
    CrossrefPubMedSearch in Google Scholar
  • 22 Pérez-Pereda S, Toriello-Suárez M, Ocejo-Vinyals G, Guiral-Foz S, Castillo-Obeso J, Montes-Gómez S. et al. Serum CGRP, VIP, and PACAP usefulness in migraine: a case – control study in chronic migraine patients in real clinical practice. Molecular Biology Reports 2020; 47: 7125-7138
    CrossrefPubMedSearch in Google Scholar
  • 23 Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS. et al. Sex hormones and calcitonin gene-related peptide in women with migraine: a cross-sectional, matched cohort study. Neurology 2023; 100: e1825-e1835
    CrossrefPubMedSearch in Google Scholar
  • 24 Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology 2012; 79: 474-479
    CrossrefPubMedSearch in Google Scholar
  • 25 Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 2005; 58: 561-568
    CrossrefPubMedSearch in Google Scholar
  • 26 Messlinger K, Vogler B, Kuhn A, Sertel-Nakajima J, Frank F, Broessner G. CGRP measurements in human plasma – a methodological study. Cephalalgia 2021; 41: 1359-1373
    CrossrefPubMedSearch in Google Scholar
  • 27 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP can monitor the different migraine phases: CGRP (in) dependent attacks. Cephalalgia. 2021 03331024211040467
    PubMedSearch in Google Scholar
  • 28 Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache: The Journal of Head and Face Pain 2006; 46: 24-33
    CrossrefPubMedSearch in Google Scholar
  • 29 Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache: The Journal of Head and Face Pain 2009; 49: 1258-1266
    CrossrefPubMedSearch in Google Scholar
  • 30 Jang MU, Park JW, Kho HS, Chung SC, Chung JW. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral diseases 2011; 17: 187-193
    CrossrefPubMedSearch in Google Scholar
  • 31 Nicolodi M, Bianco ED. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia 1990; 10: 39-50
    CrossrefPubMedSearch in Google Scholar
  • 32 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Annals of Neurology 2022; 92: 846-859
    CrossrefPubMedSearch in Google Scholar
  • 33 Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019; 39: 1535-1543
    CrossrefPubMedSearch in Google Scholar
  • 34 Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache: The Journal of Head and Face Pain 2018; 58: 33-47
    CrossrefPubMedSearch in Google Scholar
  • 35 Juhasz G, Gecse K, Baksa D. Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response. Pharmacology & Therapeutics. 2023: 108523
    PubMedSearch in Google Scholar
  • 36 Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D. et al. Mode and site of action of therapies targeting CGRP signaling. The Journal of Headache and Pain 2023; 24: 125
    CrossrefPubMedSearch in Google Scholar
  • 37 Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine 2004; 350: 1104-1110
    CrossrefPubMedSearch in Google Scholar
  • 38 Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F. Gepants – a long way to cure: a narrative review. Neurological Sciences 2022; 43: 5697-5708
    CrossrefPubMedSearch in Google Scholar
  • 39 Li D, Abreu J, Tepper SJ. A Brief Review of Gepants. Current Pain and Headache Reports 2023; 27: 479-488
    CrossrefPubMedSearch in Google Scholar
  • 40 Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X. et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014; 83: 958-966
    CrossrefPubMedSearch in Google Scholar
  • 41 Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM. et al. Ubrogepant for the treatment of migraine. New England Journal of Medicine 2019; 381: 2230-2241
    CrossrefPubMedSearch in Google Scholar
  • 42 Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 2019; 394: 737-745
    CrossrefPubMedSearch in Google Scholar
  • 43 Ailani J, Lipton BR, Goadsby JP, Guo H, Miceli R, Severt L, Finnegan M, Trugman MJ. ADVANCE Study Group. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021 Aug 19 385(8). 695-706
    CrossrefPubMedSearch in Google Scholar
  • 44 Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A. et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache: The Journal of Head and Face Pain 2022; 62: 1153-1163
    CrossrefPubMedSearch in Google Scholar